Emgality administration3


  • Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
  • Choose an area for injection (abdomen or thigh if self-injecting and buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within area) each month
  • Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: The 3 key administration steps3

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

3 Key Administration Steps: Uncap the pen, Place and unlock, Press and hold image
3 Key Administration Steps: Uncap the pen, Place and unlock, Press and hold image
3 Key Administration Steps: Uncap the pen, Place and unlock, Press and hold image
Telephone icon

Telephonic injection support and an injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548).

Emgality comes in an easy-to-use, latex-free pen for self-administration1,4

At First Use, 94% Easy to Use image

of patients in a study agreed that the Emgality pen was "easy to use" and 96% agreed that they were confident in their ability to use it4

Patient- and caregiver-rated experiences with the pen were assessed in an open-label, 12-month study. A total of 84 patients who received once-monthly injections of Emgality 120 mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use and the respondents’ confidence in their ability to use the device.5

Scroll Down Icon
Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.